Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures

NCT00988429 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

653

Enrollment

INDUSTRY

Sponsor class

Conditions

Partial Epilepsy

Interventions

DRUG: 800 mg QD Eslicarbazepine acetate
DRUG: 1200 mg QD Eslicarbazepine acetate
DRUG: Placebo

Sponsor

Bial - Portela C S.A.

Collaborators

[object Object]